RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Neuro, So what you're saying is that it's only the lack of suitable compounds that can prevent Servier from advancing Ampakines for neurodegenerative diseases, as opposed to anything relating to the ownership of those rights?

A problem with the assumption that Servier doesn't have any suitable compounds is that the proposed solution to the high impact dilemma according to Dr. Lynch is ultra short pulse dosing. Such an approach should theoretically make the side effect problems found with most high impact compounds moot. The pulse dosing approach could give new life to high impact compounds that would never have been usable using regular long term dosing. Using this new dosing method, even Servier's own benzothiadiazides or Lilly's biarylpropylsulfonamides might be given a new lease on life. And Servier has some Cortex co-developed benzamide type high impacts as well.